Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
46-60 of 4470 results
Scientists at Scripps Research Institute make Lassa virus vaccine breakthrough
Scientists at Florida’s The Scripps Research Institute (TSRI) have succeeded in modeling a key part of a virus that sickens several people in West Africa.
Drug Research > Drug Discovery & Development > News
Eisai and Charles River Laboratories extend drug discovery collaboration
Eisai and Charles River Laboratories International have agreed to extend their two-year collaboration in integrated drug discovery for another year.
Drug Research > Drug Discovery & Development > News
Sunovion receives complete response letter from FDA for SUN-101/eFlow for COPD
Sunovion Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) for SUN-101/eFlow (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and/or emphysema.
Drug Research > Drug Discovery & Development > News
Merck licenses Teijin Pharma's Alzheimer's candidate
Merck has signed a worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau.
Drug Research > Drug Discovery & Development > News
Harpoon Therapeutics raises $45m in new funding round
Harpoon Therapeutics has secured $45m in Series B financing, which included new investors Arix Bioscience, New Leaf Venture Partners and Taiho Ventures along with existing investor MPM Capital.
Drug Research > Drug Discovery & Development > News
Nektar, Takeda to explore combination cancer therapy approaches
Nektar Therapeutics and Takeda Pharmaceutical have entered into a research collaboration to explore the combination of the former’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from the cancer portfolio of Takeda.
Drug Research > Drug Discovery & Development > News
Proteorex, Corbin partner to discover ubiquitin-specific protease inhibitors
Proteorex Therapeutics has commenced its research and development collaboration with Montreal-based Corbin Therapeutics.
Drug Research > Drug Discovery & Development > News
Iterum Therapeutics raises $65m in new financing round
Ireland-based Iterum Therapeutics, which is focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, has raised $65m in a Series B investment round.
Drug Research > Drug Discovery & Development > News
Amgen submits BLA of migraine prevention drug to FDA
Amgen has submitted the Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for erenumab to prevent migraine.
Drug Research > Drug Discovery & Development > News
Bayer lymphoma candidate secures FDA priority review designation
By PBR Staff Writer
Bayer has secured priority review designation from the US Food and Drug Administration (FDA) for its investigational anti-cancer compound copanlisib to treat follicular lymphoma (FL).
Drug Research > Drug Discovery & Development > News
Biogen acquires Remedy Pharmaceuticals' stroke drug
Biogen has acquired Remedy Pharmaceuticals' Cirara, a Phase 3 candidate in development for large hemispheric infarction (LHI).
Drug Research > Drug Discovery & Development > News
IBM researchers find new method to simulate body’s immune response
IBM’s researchers have discovered how they can trigger the body’s immune response by using polymer-coated graphene sheets.
Drug Research > Drug Discovery & Development > News
XyloCor’s cardiovascular gene therapy gets FDA fast track designation
The US Food and Drug Administration (FDA) has granted Fast Track designation to XyloCor Therapeutics’ lead product candidate XC001 (AdVEGF-All6A+), a cardiovascular angiogenic gene therapy.
Drug Research > Drug Discovery & Development > News
Novartis’ Sandoz, Durect sign $293m deal for pain killer Posimir
By PBR Staff Writer
Biopharmaceutical firm Durect has entered into a development and commercialization agreement with Novartis subsidiary Sandoz for Posimir (Saber-Bupivacaine) in the US.
Drug Research > Drug Discovery & Development > News
Vivet raises €37.5m to advance gene therapies for metabolic diseases
Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.
Drug Research > Drug Discovery & Development > News
46-60 of 4470 results